1. Academic Validation
  2. Gain-of-function mutation of microRNA-140 in human skeletal dysplasia

Gain-of-function mutation of microRNA-140 in human skeletal dysplasia

  • Nat Med. 2019 Apr;25(4):583-590. doi: 10.1038/s41591-019-0353-2.
Giedre Grigelioniene # 1 2 3 Hiroshi I Suzuki # 4 Fulya Taylan 2 Fatemeh Mirzamohammadi 1 Zvi U Borochowitz 5 Ugur M Ayturk 6 Shay Tzur 7 8 Eva Horemuzova 9 10 Anna Lindstrand 2 3 Mary Ann Weis 11 Gintautas Grigelionis 2 Anna Hammarsjö 2 3 Elin Marsk 12 Ann Nordgren 2 3 Magnus Nordenskjöld 2 3 David R Eyre 11 Matthew L Warman 6 Gen Nishimura 13 Phillip A Sharp 4 14 Tatsuya Kobayashi 15
Affiliations

Affiliations

  • 1 Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • 2 Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • 3 Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
  • 4 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • 5 Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Medical Genetics Clinics, Assuta Medical Center, Haifa, Israel.
  • 6 Orthopaedic Research Labs, Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA.
  • 7 Laboratory of Molecular Medicine, Rambam Health Care Campus, Haifa, Israel.
  • 8 Genomic Research Department, Emedgene Technologies, Tel Aviv, Israel.
  • 9 Department for Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • 10 Pediatric Endocrinology Unit, Karolinska University Hospital, Stockholm, Sweden.
  • 11 Department of Orthopedics and Sports Medicine, University of Washington, Seattle, WA, USA.
  • 12 Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.
  • 13 Center for Intractable Diseases, Saitama Medical University Hospital, Saitama, Japan.
  • 14 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • 15 Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [email protected].
  • # Contributed equally.
Abstract

MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression. Heterozygous loss-of-function point mutations of miRNA genes are associated with several human congenital disorders1-5, but neomorphic (gain-of-new-function) mutations in miRNAs due to nucleotide substitutions have not been reported. Here we describe a neomorphic seed region mutation in the chondrocyte-specific, super-enhancer-associated MIR140 gene encoding microRNA-140 (miR-140) in a novel autosomal dominant human skeletal dysplasia. Mice with the corresponding single nucleotide substitution show skeletal abnormalities similar to those of the patients but distinct from those of miR-140-null mice6. This mutant miRNA gene yields abundant mutant miR-140-5p expression without miRNA-processing defects. In chondrocytes, the mutation causes widespread derepression of wild-type miR-140-5p targets and repression of mutant miR-140-5p targets, indicating that the mutation produces both loss-of-function and gain-of-function effects. Furthermore, the mutant miR-140-5p seed competes with the conserved RNA-binding protein Ybx1 for overlapping binding sites. This finding may explain the potent target repression and robust in vivo effect by this mutant miRNA even in the absence of evolutionary selection of miRNA-target RNA interactions, which contributes to the strong regulatory effects of conserved miRNAs7,8. Our study presents the first case of a pathogenic gain-of-function miRNA mutation and provides molecular insight into neomorphic actions of emerging and/or mutant miRNAs.

Figures